Poor
Not Aligned
Patient Risk:
Low
Summary
The AI-generated claims are largely about coupons/discounts, insurance and cash-pay mechanics, and generic availability. In the provided FDA label excerpt (17 Patient Counseling Information), there is no support for these claims, so alignment is poor.
Category Scores
Accurate Statements
Breo (fluticasone furoate/vilanterol) is a prescription inhaler.
Not supported or verified by the provided label excerpt (17 Patient Counseling Information).
Unsupported Statements
Breo coupons usually mean savings offers from the manufacturer’s patient assistance programs, commercial coupon/discount sites, or pharmacy-run discount cards.
No coupon/discount/patient assistance information is present in the provided label excerpt.
Coupon availability for Breo changes by ZIP code, pharmacy, and eligibility rules.
No information about coupon availability by ZIP code/pharmacy/eligibility is present in the provided label excerpt.
Coupons and copay cards typically apply only when a patient has commercial insurance.
No information about how coupons/coplay cards relate to insurance type is present in the provided label excerpt.
Many coupon/copay card offers do not reduce costs for patients on Medicare/Medicaid because of program restrictions.
No information about Medicare/Medicaid cost effects or restrictions is present in the provided label excerpt.
Some Breo coupon offers are limited to certain strengths, such as 100/25 mcg versus 200/25 mcg.
No information about coupon limitations by strength is present in the provided label excerpt.
Some Breo coupon offers require enrollment.
No information about enrollment requirements for coupons is present in the provided label excerpt.
If a patient is not using insurance, some Breo coupons may not work.
No information about coupon effectiveness for uninsured patients is present in the provided label excerpt.
For Breo when paying cash, a pharmacy discount card or a separate cash price offer may be needed.
No information about cash-pay pricing or discount cards is present in the provided label excerpt.
The result for Breo cash pricing can vary by pharmacy and whether the product is branded vs generic.
No information about cash pricing variability or branded vs generic price effects is present in the provided label excerpt.
Breo does not have a widely established generic equivalent in many markets.
No information about generic equivalents or market availability is present in the provided label excerpt.
The status of a generic equivalent for Breo depends on country and product approvals.
No information about generic-equivalent status by country/approvals is present in the provided label excerpt.
Most Breo coupon offers depend on eligibility (including age and insurance status).
No information about coupon eligibility criteria is present in the provided label excerpt.
Most Breo coupon offers depend on whether the coupon is accepted at the patient’s specific pharmacy.
No information about coupon acceptance by pharmacy is present in the provided label excerpt.
Most Breo coupon offers depend on the Breo dose/strength and the inhaler device formulation.
No information about coupon dependence on dose/strength/device formulation is present in the provided label excerpt.
Most Breo coupon offers depend on the expiration date and any limits such as up to a monthly fill.
No information about coupon expiration dates or fill limits is present in the provided label excerpt.
Coupon availability for Breo is usually driven by payer coverage and manufacturer contracting rather than patent status.
No information about drivers of coupon availability (payer coverage/manufacturer contracting/patent status) is present in the provided label excerpt.
Branded inhalers can have long market exclusivity periods that keep prices high, which can make savings programs more common.
No information about market exclusivity, pricing drivers, or prevalence of savings programs is present in the provided label excerpt.
Contradictions
Important Omissions
Key FDA-required safety and use information (e.g., boxed warnings, contraindications, dosage & administration, monitoring) relevant to Breo was not addressed by the AI claims and cannot be assessed from the provided label excerpt.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
The AI claims evaluated here concern coupons/pricing/logistics and do not themselves describe dosing or specific patient safety instructions from the label excerpt. However, the lack of label-aligned safety content prevents assessment of clinically relevant guidance.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are about coupons/discounts/insurance and are not supported by the provided FDA label excerpt (17 Patient Counseling Information).
Suggested Improvement
Limit claims to information explicitly present in the provided label excerpt (e.g., patient counseling points such as not for acute symptoms, not using additional LABAs, and counseling on specific risks) and omit coupon/pricing/generic-market assertions unless supported by the provided label text.